BurnsAdler Expands Puerto Rico Franchise

Charlotte, North Carolina (February 9, 2005) - BurnsAdler Pharmaceuticals, Inc. announced today that they have partnered with QOL Medical, LLC for the promotion and distribution of Sucraid® (sacrosidase) Oral Solution in Puerto Rico. Sucraid® is the first and only pharmacologic therapy approved by the FDA as a simple, safe and effective enzyme replacement therapy of the genetically determined sucrase deficiency, which is part of congenital sucrase-isomaltase disease (CSID).

Bryan Somerville, Executive Vice President of BurnsAdler remarked, "Sucraid® is an excellent niche gastroenterology product that will dramatically increase the quality of life for children with CSID. We continue to focus on expanding our franchise in Puerto Rico, where products are often never launched or are under utilized when compared to the U.S. Mainland. In addition to Sucraid® we are planning on launching our viscosupplement, NeoVisc®, immediately upon receipt of FDA approval."

Ron Morris, Vice President of QOL Medical added, "We are excited to partner with BurnsAdler in Puerto Rico. We believe Sucraid® will be successful in both filling an unmet medical need and improving patient's lives in Puerto Rico."

BurnsAdler is a specialty pharmaceutical company that in-licenses and promotes products in Europe, South America, Mexico, Canada, Puerto Rico and the Caribbean. BurnsAdler's portfolio currently includes products in the following fields: cardiovascular, orthopaedic, oncology and epilepsy. QOL Medical LLC, headquartered in Mooresville, North Carolina, is a specialty pharmaceutical development and commercialization company dedicated to improving quality of life for the patients they serve, their families and caregivers.

For additional information about this news release contact Bryan Somerville at +1.704.552.8410 Ext. 223. For additional information about BurnsAdler, please refer to the company's website at www.burnsadler.com.

For additional information about QOL Medical LLC, please refer to the company's website at www.qolmed.com.